Global Generics (GGJ) posted Q2 FY26 revenues of ₹8,500 crore, up 10% YoY and 4% QoQ, with H1 FY26 revenues at ₹15,410 crore, up 10% YoY. North America revenues declined to ₹3,240 crore in Q2 FY26, down 13% YoY and 5% QoQ, with H1 FY26 revenues at ₹6,650 crore, down 12% YoY. Shares of Dr Reddy’s Laboratories Ltd ended at ₹1,282.70, up by ₹3.30, or 0.26%, on the BSE.
